Founded in July 2010 in Halle an der Saale, Crewpharm specializes as Marketing Authorization Holder (MAH) in the manufacture, trade and distribution of generics, pharmaceuticals and drugs. The focus is on generics and biosimilars.


The productions are carried out in close cooperation with German and international manufacturers according to GMP.


When choosing our partners, compliance with the highest European quality standards is crucial. Comprehensive quality assurance guarantees physicians, pharmacists and patients the highest level of product purity through comprehensive control and documentation.


The product portfolio is continuously expanded due to ongoing research and current market requirements.

Crewpharm GmbH
Pharmaceutical Company & Pharmaceutical Wholesale
Dölbau, Orionstraße 1, (Industriepark Star Park A 14)
06184 Kabelsketal / Dölbau, Germany

Tel. + 49-345-279-532-0

info@crewpharm.com

www.crewpharm.com

Go to article: Home | The Dawn of Big DataGo to article: EditorialGo to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: ContentsGo to article: Daiichi JitsugyoGo to article: How will Amazon's acquisition of online pharmacy business PillPack disrupt the pharmaceutical industry? Go to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Fentanyl: where did it all go wrong?Go to article: NSFGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: Turning up the heat on nano researchGo to article: TSS Company InsightGo to article: TSS ABGo to article: MedelpharmGo to article: Cracking the mystery of Alzheimer's diseaseGo to article: Röchling Medical NeuhausGo to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: Where are the world's pharma manufacturing hotspots?Go to article: Gerteis Company InsightGo to article: GerteisGo to article: ZenatekGo to article: How India’s use of unapproved antibiotics could undermine global healthGo to article: Novo Nordisk PharmatechGo to article: Phoenix Company InsightGo to article: PhoenixGo to article: CRISPR: a seismic shift in gene editingGo to article: CBDepot Company InsightGo to article: CBDepotGo to article: Is the UK’s drug evaluation system in need of an overhaul?Go to article: Nelson Labs Company InsightGo to article: Nelson LabsGo to article: Centaur Clinical | Company InsightGo to article: Centaur ClinicalGo to article: Opening up the Chinese drug marketGo to article: Finnair Cargo | Company InsightGo to article: Finnair CargoGo to article: Immunising against opioids – could a vaccine solve the crisis? Go to article: Molnar Company InsightGo to article: MolnarGo to article: PharmasolGo to article: The next generation of antimalarials Go to article: Oncology Therapeutic Development Company InsightGo to article: Oncology Therapeutic DevelopmentGo to article: Pharma Support Services Company InsightGo to article: Pharma Support ServicesGo to article: The People vs Big Pharma: tackling the industry’s trust issuesGo to article: G.F.Go to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: Amazon and PillPack: an unstoppable pharmacy force?Go to article: BEAGo to article: Buchi Labortechnik AG Company InsightGo to article: Buchi Labortechnik AGGo to article: Is the microbiome as important for precision medicine as genetics?Go to article: Medical HempGo to article: Senn ChemicalsGo to article: Senn ChemicalsGo to article: Niconex Medical LtdGo to article: HPV vaccines: a decade of progressGo to article: Med-Script AssociatesGo to article: B&W Tek | Company InsightGo to article: B&W TekGo to article: EventsGo to article: CG ChemikalienGo to article: AlpexGo to article: Next issueGo to article: Pall Biotech Company InsightGo to article: CrewpharmGo to article: EndocaGo to article: Diversey